Pressure BioSciences, Inc. · OTC:PBIO
Pressure BioSciences — SeeThruEquity Winter Microcap Investor Conference (February 2015)
19 slides from Pressure BioSciences's conference presentation, Feb 11, 2015
Slide 1: Investor Presentation: Pressure BioSciences, Inc.
Investor Presentation Pressure BioSciences, Inc. (OTCQB: PBIO) Discovery Starts with Sample Preparation™ SeeThruEquity Winter Microcap Investor Conference February 5, 2015 Richard T. Schumacher PBI President, CEO
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain forward looking statements that reflect management's current views and opinions as to the status of the Company’s products, technology and other future events and operations. These statements are neither a promise nor guarantee, but involve ri
Slide 3: Company Overview
Company Overview (OTCQB: PBIO) ¢ 10FT Staff; Near Boston,MA; Publicly Traded (OTCQB: PBI) ¢ Market Cap (fully diluted): $8.3Million « 24 Patents: Pressure Cycling Technology (“PCT”) Platform * Develop, Mfg, & Sell PCT-based Instruments & Consumables ¢ Initial Focus in Sample Preparation for the Rese
Slide 4: Experienced Senior Management & Board
perienced Senior Management & Board Management + Mr.Richard T. Schumacher, President & CEO Boston Biomedica (CEO, Founder); Panacos Pharma (President, Co-founder); Trinity Biotech (Founding Group); CBR Labs (Gen’ | Mgr) - Harvard Medical School + Dr. Edmund V. Ting, Senior Vice President of Engineer
Slide 5: Primary Sample Preparation for Biomolecular Analysis: Cell Lysis
Primary Sample Preparation for Biomolecular Analysis: Cell Lysis
Slide 6: Sample Input Quality = Sample Result Quality
Sample Input Quality = Sample Result Quality Scientific research can be broken down to three key elements: sample preparation, analysis, & data reduction/interpretation PB I “Discovery Starts with Sample Preparation” r
Slide 7: Value Proposition: PCT-based biological sample preparation
Value Proposition: PCT-based biological sample preparation + Analysis of DNA, RNA, Proteins, & Lipids (“biomolecules”) is Crucial to the Discovery of New Biomarkers — Quality Depends on Quality of Preparation * Biological Sample Preparation is a Multi-Billion Market Comprised of an Estimated 500,000
Slide 8: Biomarker/Forensics Market: Estimated Size
Biomarker/Forensics Market: Estimated Size Estimated Market * Genomics (DNA/RNA) $7.1B in 2015 > * Next Gen Sequencing (DNA) $2.7B in 2017¢ * Mass Spectrometry (Proteins) $2.7B in 201124 * Forensic Tools and Products (DNA) $17.7B in 2019 © * Sample Prep for all OMICS: $8.4B in 2016 * 500,000 Scienti
Slide 9: Selected Marquee Customers (150)
Selected Marquee Customers (150) C LLP Eee HARVARD tt EA MEDICAL SCHOOL MONSANTO ¥ D> National Institutes of Health ipt U.S.ARMY
Slide 10: PCT Focus Area Biomarker Discovery & Forensics
PCT Focus Area marker Discovery & Forensics Biomarker Discovery: Cancer, Heart Disease, Stroke, Inf. Diseases, Etc. Dr. Andreas Huhmer— Thermo Fisher Scientific Dr. Michael Alterman - Tumor Vaccines and Biotechnology Branch, CBER, FDA Dr. Alexander lvanov—Harvard School of Public Health Dr. Jennifer
Slide 11: Competitive Landscape
Competitive Landscape Nearly All Competitive Methods YS Involve Mechanical Disruption eZ Mortar & Pestle X 7 Dounce homogenizer (glass on glass) ” Potter-Elvenhjem homogenizer (Teflon on glass) Enzymatic Digestion | Polytron shearing homogenizers Blenders Bead Beating Sonication Repeated Freeze/Thaw
Slide 12: PCT Sample Preparation System
PCT Sample Preparation System = =n Ci — Barocycler™ wi NEP2320 Barocycler™ NEP3229 PULSE Tube PCT-dependent Kits PBI MicroTubes 1
Slide 13: Automated liquid handling helps ensure accuracy and reproducibility
Automated liquid handling helps ensure accuracy and reproducibility, eliminates repetitive tasks, and frees personnel for other activities.
Slide 14: The Solution (4 years in the making)
he Solution (4 years in the making, ¢ Initial Application: — High pressure digestion ¢ Consumable: — Proprietary 8-well strips « Number of Samples: — 48 samples ¢ User Control: — Easy to use touch screen — LabView Software 15
Slide 15: The Future (is now)
The Future (is now) PBI 16
Slide 16: A Look at Several Scientific and Business Supporters
A Look at Several Scientific and Business Supporters Distinguished Prof: UCLA School of Medicine Member, Nat’l Academy of Sciences Gold Medal, International EPR Society Research: Structure & Function Proteins Prof Wayne Hubbell Prof of Medicine, Cedars-Sinai Med. Ctr. Director, Barbara Streisand Wom
Slide 17: Recent milestones: Dec 2014 PIPE and Barozyme HT48 evaluations
Dec 2014 $903K PIPE: 30 warrant holders exercised 3,612,000 warrants Dec 2014 3 Barozyme HT48 Evaluation Begins: Feinberg SoM (NW Univ) Nov 2014 41st & 2"¢ Barozyme HT48 Evaluations Begin Nov 2014 Q3 Financial Results: Product revenue up, operating costs down Oct 2014 Breakthrough Method to Permit Q
Slide 18: Key Investment Highlights
Key Investment Highlights + Pressure Cycling Technology (PCT): Powerful, Enabling, Patented Proven Technology: ~ 250 Installations in ~150 Marquee Laboratories Experienced Management Team and Board of Directors Large Market Opportunity (est. $6 Billion; 80k Labs) Closed PIPES of $3.3M (Dec 2013 to N
Slide 19: Breaking News
Breaking News ® 1st High Throughput Barozyme HT48 System Sold! PO Received on Feb 4th From Evaluation Site #1 Leading Biotech Company Already Own and Routinely Use Two Barocyclers Barozyme HT48 Expected Use in Many Depts (R&D, Mfg) Excellent Evaluation Data ° Quote Requested From European Company ®
Pressure Biosciences — SeeThruEquity Winter Microcap Investor Conference (February 2015) on 6ix